The global antibody production market size was valued at USD 7.4 billion in 2016 and is projected to grow at 13.5% over the forecast period. The increasing focus of biopharmaceutical & biotechnology companies for the production of antibody therapeutics is a major factor driving the growth. These therapeutics are highly effective in the treatment of rheumatoid arthritis, cancer, and other chronic diseases. Thus, the production of therapeutic antibodies is increasing, which is expected to drive the growth of the market during the forecast period.
There has been an increase in R&D activities by many pharmaceutical and biotechnology companies to develop advanced biologics including monoclonal antibodies. Focus on R&D is an essential strategy to drive the long-term growth of the company. Several pharmaceutical and biotechnology companies are undergoing partnerships and collaborations to gain leadership in the sector. For instance, in June 2016, Novartis and Xencor Inc. entered into a strategic collaboration and licensing agreement. According to this agreement, Novartis received rights to develop XmAb 14045 and XmAb 13676 (T-cell-engaging bispecific antibodies) for the treatment of B-cell malignancies and acute myeloid leukemia.
U.S. antibody production market, by type, 2014 - 2025 (USD Million)
On the basis of type, the antibody production market is segmented into polyclonal antibodies and monoclonal antibodies. In 2016, the monoclonal antibody segment was the highest revenue-generating segment of the market, due to increasing investment in monoclonal antibody research and a large number of antibody-based product launches. Thus, the growing adoption of these products is expected to be the key factor driving the antibody production products market.
The polyclonal antibodies segment is expected to exhibit a significant growth rate during the forecast period. Polyclonal antibodies provide several advantages such as easy production process, availability at a low price, and diagnosis of diseases with high proficiency. Thus, the popularity of these products is increasing, which is projected to drive segment growth.
North America antibody production market share, by end-use, 2016 (%)
The downstream processing segment is reported to have the largest revenue share of the antibody production industry in 2016 and is projected to grow at the highest CAGR during the forecast period. This procedure involves the use of highly sophisticated, accurate, and efficient products including chromatography instruments & resins.
The upstream processing and filtration segment is expected to exhibit lucrative growth during the forecast period. Product advancement and growing investment in production infrastructure by manufacturers is a prime factor endorsing the growth of this segment. The manufacturers are using advanced bioreactors and filtration systems for the production process to assure the superior quality of the end-product.
On the basis of end-use, the antibody production industry is segmented into pharmaceutical & biotechnology companies, research laboratories, and others. The pharmaceutical & biotechnology companies are reported to have the largest revenue share of the market in 2016. A large application of these products in the production of antibodies is the predominant factor contributing to its largest share. Furthermore, since product purification is very crucial in the entire production process, companies invest a large amount of money for this procedure.
The research laboratories was the second-highest revenue-generating segment of the market, owing to increasing investment in antibody-based research and drug discovery. This segment is expected to grow at a significant CAGR during the forecast period.
North America dominated the overall market with the largest revenue share, due to the presence of many large biotechnology and biopharmaceutical firms in this region. In addition, factors such as the highly developed healthcare & research infrastructure and increased focus on drug discovery in North America have fueled the regional market growth.
The Asia Pacific is expected to exhibit the highest growth during the forecast period, owing to untapped opportunities in this region. There are many biopharmaceutical and clinical research organizations companies, which are targeting Asian countries, such as China & India for drug discovery and development. The presence of less stringent regulations for antibodies development & production, vast genome pool, and developing healthcare infrastructure in this region are some of the major factors contributing to the growth of the sector in this region.
Some of the key players are Thermo Fisher Scientific, Inc.; GE Healthcare; Sartorius AG; Merck KGaA; Eppendorf AG; Cellab GmbH; Pall Corp.; INTEGRA Biosciences AG; and FiberCell Systems Inc. The major companies are undertaking various strategies initiatives, such as new product development, mergers & acquisitions, collaborations, and regional expansion for serving the unmet needs of their customers.
Strategic collaborations or acquisitions help vendors expand their existing product portfolio and geographical reach. For instance, in November 2015, Merck completed the acquisition of Sigma-Aldrich Corp., a leading life science company. Post this acquisition, Merck has more than 50,000 employees, 72 manufacturing sites, and a presence in 67 countries worldwide.
|
Attribute |
Details |
|
Base year for estimation |
2016 |
|
Actual estimates/Historical data |
2014 - 2016 |
|
Forecast period |
2017 - 2025 |
|
Market representation |
Revenue in USD Million and CAGR from 2017 to 2025 |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America & MEA |
|
Country scope |
U.S., Canada, UK, Germany, Japan, India, China, Brazil, Mexico, South Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
|
15% free customization scope (equivalent to 5 analyst working days) |
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the antibody production market on the basis of type, process, end-use, and region:
Type Outlook (Revenue, USD Million; 2014 - 2025)
Polyclonal antibody
Monoclonal antibody
Murine
Chimeric
Humanized
Process Outlook (Revenue, USD Million; 2014 - 2025)
Upstream processing
Bioreactors
Large-scale bioreactors
Single-use bioreactors
Consumables
Media
Buffers and reagents
Downstream processing
Chromatography systems
Chromatography resins
Filtration
Filtration systems
Filtration consumables and accessories
End-use Outlook (Revenue, USD Million; 2014 - 2025)
Pharmaceutical and biotechnology companies
Research laboratories
Others
Regional Outlook (Revenue, USD Million; 2014 - 2025)
North America
The U.S.
Canada
Europe
Germany
The U.K.
Asia Pacific
Japan
China
India
Latin America
Brazil
Mexico
MEA
South Africa
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
